A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo controlled trial of Dantrolene (N= 84 participants) to
demonstrate the feasibility of using I.V. dantrolene to study the effect of RyR2 inhibition
on cardiac electrophysiology, hemodynamics and ventricular arrhythmia inducibility in
patients with structural heart disease referred for VT ablation. The investigators will also
explore the pharmacokinetic/pharmacodynamic relationship of I.V. dantrolene and it short-term
effect on specific cardiac electrophysiologic and hemodynamic parameters.